Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

NCT03671590 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

172

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic/Business Decision

Conditions

Non Hodgkin Lymphoma
Chronic Lymphocytic Leukemia

Interventions

DRUG: TG-1701
DRUG: Umbralisib
BIOLOGICAL: Ublituximab

Sponsor

TG Therapeutics, Inc.